Lu Yifan, Xie Yixuan, Yang Xinyi, Nie Lijuan, Cheng Zhe, He Yixian, Lv Tiansu, Wu Qibiao, Zhou Xiqiao
State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, People's Republic of China.
The First Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing City, 210000, Jiangsu Province, China.
Hormones (Athens). 2025 Jun 26. doi: 10.1007/s42000-025-00688-6.
Diabetic gastroparesis is a common complication of diabetes, characterized by delayed gastric emptying, significantly impacting patients' quality of life. Current treatment options are limited often resulting in unsatisfactory outcomes. This meta-analysis aims to evaluate the efficacy and safety of cisapride in diabetic patients suffering from gastroparesis.
A systematic literature search identified 13 studies involving 185 participants. Data on gastric emptying rates, symptom relief, and safety profiles were extracted and analyzed. Effectiveness was measured through gastric emptying half-life (T1/2, measured in min), 120-min gastric emptying rate (measured as a percentage), and adverse events.
The analysis revealed that cisapride significantly improved gastric emptying compared to placebo, with a mean difference (MD) of -33.74 for T1/2 (95% CI: -68.84 to -2.65, P = 0.03). Additionally, the 120-min gastric emptying rate improved by -25.84 (95% CI: -16.80 to -25.84, P < 0.001). The occurrence of adverse events was low, with most patients tolerating the treatment well.
Cisapride demonstrates notable efficacy in improving gastric emptying in diabetic gastroparesis, with a generally acceptable safety profile. Clinicians should consider cisapride as a viable treatment option while monitoring patients for any potential side effects. Further research is warranted to explore long-term safety and effectiveness.
糖尿病性胃轻瘫是糖尿病常见的并发症，其特征为胃排空延迟，严重影响患者的生活质量。目前的治疗选择有限，常常导致不尽人意的结果。本荟萃分析旨在评估西沙必利对糖尿病性胃轻瘫患者的疗效和安全性。
通过系统的文献检索，确定了13项研究，涉及185名参与者。提取并分析了关于胃排空率、症状缓解及安全性的数据。通过胃排空半衰期（T1/2，以分钟为单位）、120分钟胃排空率（以百分比表示）和不良事件来衡量有效性。
分析显示，与安慰剂相比，西沙必利显著改善了胃排空，T1/2的平均差值（MD）为 -33.74（95%可信区间：-68.84至 -2.65，P = 0.03）。此外，120分钟胃排空率提高了 -25.84（95%可信区间：-16.80至 -25.84，P < 0.001）。不良事件的发生率较低，大多数患者对治疗耐受性良好。
西沙必利在改善糖尿病性胃轻瘫患者的胃排空方面显示出显著疗效，且安全性总体上可接受。临床医生在监测患者是否有任何潜在副作用的同时，应将西沙必利视为一种可行的治疗选择。有必要进一步研究以探索其长期安全性和有效性。
